Usage: BEIZRAY, in combination with cisplatin and fluorouracil, is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Usage: ERBITUX is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), recurrent or metastatic SCCHN, K-Ras wild-type metastatic colorectal cancer (mCRC), and BRAF V600E mutation-positive mCRC in combination with specific therapies. It is not for Ras-mutant cancers.